Long noncoding RNA NORAD regulates lung cancer cell proliferation, apoptosis, migration, and invasion by the miR-30a-5p/ADAM19 axis.

CONCLUSION: NORAD knockdown suppressed cell proliferation, migration and invasion but promoted cell apoptosis in lung cancer cells by regulating miR-30a-5p/ADAM19, providing a possible therapeutic strategy for lung cancer patients. PMID: 32055266 [PubMed]
Source: International Journal of Clinical and Experimental Pathology - Category: Pathology Authors: Tags: Int J Clin Exp Pathol Source Type: research

Related Links:

Publication date: Available online 30 May 2020Source: Cancer CellAuthor(s): Abbie S. Ireland, Alexi M. Micinski, David W. Kastner, Bingqian Guo, Sarah J. Wait, Kyle B. Spainhower, Christopher C. Conley, Opal S. Chen, Matthew R. Guthrie, Danny Soltero, Yi Qiao, Xiaomeng Huang, Szabolcs Tarapcsák, Siddhartha Devarakonda, Milind D. Chalishazar, Jason Gertz, Justin C. Moser, Gabor Marth, Sonam Puri, Benjamin L. Witt
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Publication date: Available online 31 May 2020Source: Materials Science and Engineering: CAuthor(s): Vineela Parvathaneni, Nishant S. Kulkarni, Gautam Chauhan, Snehal K. Shukla, Rasha Elbatanony, BrijeshKumar Patel, Nitesh K. Kunda, Aaron Muth, Vivek Gupta
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Propofol suppresses the progression of non‑small cell lung cancer via downregulation of the miR‑21‑5p/MAPK10 axis. Oncol Rep. 2020 May 21;: Authors: Wu X, Li X, Xu G Abstract Non‑small cell lung cancer (NSCLC) accounts for>80% of lung cancer cases and is the leading cause of cancer‑associated mortality worldwide. Propofol is an anesthetic drug frequently used during tumor resection. It is also known to exert inhibitory effects on cancer. Although the role of propofol in NSCLC has been reported, its underlying mechanisms remain unknown. The present study aimed therefore to investigate the m...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Knockdown of ubiquitin‑specific protease 51 attenuates cisplatin resistance in lung cancer through ubiquitination of zinc‑finger E‑box binding homeobox 1. Mol Med Rep. 2020 May 27;: Authors: Zhou F, Du C, Xu D, Lu J, Zhou L, Wu C, Wu B, Huang J Abstract Lung cancer is a devastating cancer with high morbidity and mortality. Ubiquitin‑specific protease (USP) is a type of deubiquitinating enzyme (DUB) that has been implicated in numerous cancers, including colorectal, myeloma and breast. In the present study, the expression of USP51 was determined in the lung cancer cell line A549 and cisplatin (a...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Effect of AGER on the biological behavior of non‑small cell lung cancer H1299 cells. Mol Med Rep. 2020 May 22;: Authors: Wang Q, Zhu W, Xiao G, Ding M, Chang J, Liao H Abstract Advanced glycosylation end-product specific receptor (AGER) is a multi-ligand cell surface receptor abnormally expressed in lung cancer, and is a member of the immunoglobulin superfamily. Therefore, this study aimed to explore the effect of AGER on the biological behavior of non‑small cell lung cancer (NSCLC) H1299 cell line. A microarray‑based gene expression profiling analysis of the GSE27262 dataset from the Gene Expres...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Publication date: Available online 29 May 2020Source: The Lancet Respiratory MedicineAuthor(s): Yi-Long Wu, Ying Cheng, Jianying Zhou, Shun Lu, Yiping Zhang, Jun Zhao, Dong-Wan Kim, Ross Andrew Soo, Sang-We Kim, Hongming Pan, Yuh-Min Chen, Chih-Feng Chian, Xiaoqing Liu, Daniel Shao Weng Tan, Rolf Bruns, Josef Straub, Andreas Johne, Jürgen Scheele, Keunchil Park, James Chih-Hsin Yang
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Publication date: Available online 29 May 2020Source: The Lancet Respiratory MedicineAuthor(s): Rafael Rosell, Imane Chaib, Mariacarmela Santarpia
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
[WHO] Nairobi -Much earlier in her life, Martha Kombe, now 24, watched someone close to her fight lung cancer and lose. Since then she has made a vow to help people avoid the agony that comes with such a painful disease.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Overall survival (OS) benefit derived from frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer was further improved after at least 12 months of follow-up.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
We examined 329 patients from February 2002 to July 2013. There were 131 MPM cases with ADA levels of 32.29 IU/L; 117 LC cases with ADA levels of 21.12 IU/L; 54 benign disease cases with ADA levels of 20.98 IU/L. A significant difference existed in pleural effusion ADA levels between MPM and benign disease patients. Pleural effusion ADA levels were significantly higher in MPM patients. PMID: 32468861 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Pathology